Dr. Karim Fizazi and Dr. Bertrand Tombal presented a debate on “Hormone-Naive Metastatic Prostate Cancer Patients Should Get Chemotherapy and ADT as a Standard of Care” versus “ADT and AR Pathway Targeted Agents Still Have a Role in These Patients” at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between October 14th and 16th 2016.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
Keywords: de novo metastatic prostate cancer, ADT, Docetaxel
How to cite: Fizazi, Karim and Tombal, Bertrand. “Prostate Cancer Patients Should/Should Not Get Chemo and ADT as a Standard of Care” Grand Rounds in Urology. October 14-16, 2016. Accessed Nov 2024. https://grandroundsinurology.com/debate-prostate-cancer-patients-shouldshould-not-get-chemo-adt-standard-care
This presentation was made at the 6th Symposium on the Treatment of Prostate Cancer (STOP-6), which was held in Lisbon, Portugal between the 14th and 16th October.
STOP-6 was accredited for CME by the European Accreditation Council for CME (UEMS-EACCME).
The meeting was organized by Bioscript and the Scientific Committee, composed of Professors Laurence Klotz (Chair), Noel Clarke, Karim Fizazi and Bertrand Tombal.
Funding to support this educational activity was provided by FERRING Pharmaceuticals. FERRING did not influence meeting content and the views expressed during the meeting represent only those of the faculty.
ABOUT THE AUTHOR
Bertrand Tombal, MD, PhD, is Professor of Physiology and Chair of the Division of Urology at the Université catholique de Louvain and its associated hospital, the Cliniques universitaires Saint-Luc, in Brussels, Belgium. He obtained his MD in 1990 and his PhD in 2003, both from the Université catholique de Louvain, and completed part of his science training at Johns Hopkins University in Baltimore, Maryland. Professor Tombal has both a scientific and a clinical interest in urological oncology, particularly in the areas of prostate and bladder cancer. While pursuing his PhD, he investigated the mechanisms of apoptosis in prostate cancer cells and the modulation of apoptosis by growth factors. His primary clinical interest is the treatment of the advanced stages of prostate cancer, and particularly hormonal treatment and the development of new biological agents. As Head of the Uro‐Oncology Division at the Université catholique de Louvain, he is currently coordinating several clinical trials in this research area. Professor Tombal has authored many peer‐reviewed articles and books or book chapters. He has presented at numerous national and international conferences and has been the recipient of various awards for his research in the field of urology, including the European Association of Urology Thesis Award, which he received in 2003. Professor Tombal is also a member of the Scientific Office of the European Association of Urology.
